| Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy S Rashdan, JD Minna, DE Gerber The Lancet Respiratory Medicine 6 (6), 472-478, 2018 | 86 | 2018 |
| Salvage therapy for patients with germ cell tumor S Rashdan, LH Einhorn Journal of oncology practice 12 (5), 437-443, 2016 | 36 | 2016 |
| NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non … P Iyengar, C Hu, DR Gomez, RD Timmerman, CB Simone, CG Robinson, ... Journal of Clinical Oncology 42 (16_suppl), 8506-8506, 2024 | 23 | 2024 |
| Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice S Rashdan, DE Gerber Translational Lung Cancer Research 8 (3), 202, 2019 | 20 | 2019 |
| Nintedanib for the treatment of non-small-cell lung cancer S Rashdan, N Hanna Expert opinion on pharmacotherapy 15 (5), 729-739, 2014 | 19 | 2014 |
| Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies S Rashdan, DE Gerber Annals of translational medicine 4 (24), 2016 | 14 | 2016 |
| Humoral and cellular correlates of a novel immune-related adverse event and its treatment AS Gonugunta, MS Von Itzstein, H Mu-Mosley, F Fattah, JD Farrar, ... Journal for Immunotherapy of Cancer 9 (12), 2021 | 12 | 2021 |
| A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer S Rashdan, DE Gerber Translational cancer research 6 (Suppl 1), S78, 2017 | 11 | 2017 |
| The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer A Kalra, S Rashdan Frontiers in Oncology 13, 1158417, 2023 | 10 | 2023 |
| Prevalence and significance of potential pharmacokinetic drug–drug interactions among patients with lung cancer: implications for clinical trials S Rashdan, H Yang, T Le, C Selby, DE Gerber, CA Alvarez Clinical Drug Investigation 41, 161-167, 2021 | 10 | 2021 |
| Antibiotic prescriptions in lung cancer and melanoma populations: Differences with potential clinical implications in the immunotherapy era AS Gonugunta, MS Von Itzstein, D Hsiehchen, T Le, S Rashdan, H Yang, ... Clinical lung cancer 24 (1), 11-17, 2023 | 8 | 2023 |
| Potential impact of revised NCI eligibility criteria guidance: Prior malignancy exclusion in breast cancer clinical trials M Perez, CC Murphy, SL Pruitt, S Rashdan, A Rahimi, DE Gerber Journal of the National Comprehensive Cancer Network 20 (7), 792-799. e4, 2022 | 6 | 2022 |
| Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): Results from a multi … S Rashdan, S Sampath, P Iyengar, J Dowell, C Ahn, KD Westover, ... Journal of Clinical Oncology 42 (16_suppl), 8518-8518, 2024 | 5 | 2024 |
| Management of immune-related adverse events in patients with non-small cell lung cancer M Burke, S Rashdan Frontiers in oncology 11, 720759, 2021 | 5 | 2021 |
| Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer S Rashdan, P Iyengar, JD Minna, DE Gerber Translational Lung Cancer Research 10 (7), 3351, 2021 | 5 | 2021 |
| Consensus interferon plus ribavirin therapy in patients who are nonresponders or relapsers to prior PEG IFN plus ribavirin RH Ghalib, CD Levine, DA Friedman, S Rashdan, AG Schwartz, ... Gastroenterology 132 (4), A794-A794, 2007 | 5 | 2007 |
| QTc interval-prolonging medications among patients with lung cancer: implications for clinical trial eligibility and clinical care T Le, H Yang, S Rashdan, MS Link, VG Zaha, C Alvarez, DE Gerber Clinical lung cancer 21 (1), 21-27. e5, 2020 | 4 | 2020 |
| A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non … S Rashdan, JN Williams, P Currykosky, F Fattah, J Padro, ... Journal of Clinical Oncology 36 (15_suppl), e21043-e21043, 2018 | 3 | 2018 |
| pan-MHC and cross-species prediction of T cell receptor-antigen binding Y Han, Y Yang, Y Tian, FJ Fattah, MS Itzstein, M Zhang, X Kang, DM Yang, ... bioRxiv, 2023.12. 01.569599, 2023 | 1 | 2023 |
| Patterns of failure in metastatic non-small cell lung cancer patients after initiation of pembrolizumab S All, P Iyengar, KD Westover, H Choy, S Rashdan, J Lohrey, R Hughes, ... International journal of radiation oncology, biology, physics 111 (3), e420, 2021 | 1 | 2021 |
